Patients with HIV infections and the *22/*22 genotype may have decreased clearance of lopinavir as compared to patients with the *1/*1 or *1/*22 genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.